Clinical Trial Detail

NCT ID NCT02485535
Title Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Chicago
Indications

bone marrow cancer

acute myeloid leukemia

Therapies

Selinexor

Age Groups: adult

No variant requirements are available.